Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 16/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 12/20 | 0.71 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.67 |
| ▸ | MDM4 | O15151 | 1/20 | 0.66 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | BID | P55957 | 1/20 | 0.66 |
| ▸ | BAX | Q07812 | 1/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | ASPH | Q12797 | 1/20 | 0.66 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.66 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.66 |
| ▸ | BAD | Q92934 | 1/20 | 0.66 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744739 | 0.89 | BCL2 (0.67) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL2994558 | 0.89 | BCL2 (0.71) | BCL2BCL2L1BAK1 | |
| SCHEMBL1540127 | 0.87 | BCL2L1 (0.67) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL1541585 | 0.86 | BCL2 (0.72) | BCL2 | |
| SCHEMBL2990459 | 0.86 | BCL2 (0.79) | BCL2BCL2L1BAK1 | |
| SCHEMBL1743047 | 0.86 | BCL2 (0.63) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL1743602 | 0.86 | — | — | |
| SCHEMBL1540976 | 0.85 | BCL2L1 (0.75) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL1540607 | 0.85 | BCL2L1 (0.66) | BCL2BCL2L1BAK1MDM4BCL2L11 | |
| SCHEMBL1540547 | 0.85 | BCL2L1 (0.69) | BCL2BCL2L1BAK1MDM4BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885BAK1 9/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885BAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.